Tuneable Conditional Control of Engineered Bacterial Therapeutics

This project aims to develop a modular synthetic receptor platform for precise control of engineered bacteria in cancer therapy, enhancing safety and efficacy through conditional therapeutic release.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

Engineered microbes are attractive platforms for the diagnosis and treatment of several diseases. For example, bacteria can selectively target tumors and are ideal vehicles for in situ delivery of therapeutic agents.

Current Limitations

However, as of today, no engineered living bacterial therapeutics in clinical trials have the ability for conditional control of therapeutic activity. This lack of reliable control over the timing and dosage of effector molecule production limits the specificity, safety, and efficacy of current bacterial therapies.

Project Overview

In this project, I will use a generalizable synthetic receptor platform to control the in vivo therapeutic activity of engineered bacteria using externally administered molecules. As a proof of concept, I will use a receptor responding to a molecule found in the diet to control therapeutic release in tumors. I will use a safe probiotic, E. coli Nissle 1917, with demonstrated tumor targeting properties.

Research Lines

First Research Line

  1. I will characterize the dose-response and kinetics of synthetic receptors implemented in bacteria colonizing an in vitro 3D tumor spheroids model.
  2. I will then evaluate the therapeutic activity of strains producing cytolytic molecules in response to external inducer.

Second Research Line

  1. I will characterize conditional control of gene expression.
  2. I will then assess therapeutic release in a tumor mice model, using cytolytic and immunotherapeutic effectors.

Expected Outcomes

My work will deliver robust, safe, and efficient frameworks for conditional control of bacterial cancer therapy. By enabling in situ drug delivery with a highly precise dosage and timing, it will allow physicians and ultimately the patients to finely control bacterial therapeutic activity.

Future Applications

Because of its modularity, my platform will be further engineerable to detect other conditional inducers. This system will be reusable for the treatment of many other pathologies, including autoimmune and infectious diseases.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-4-2023
Einddatum31-3-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEpenvoerder

Land(en)

France

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC COG

In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR

This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.

€ 1.999.780
ERC COG

ModulatIng Cancer therapy RespOnse using Bacterial Extracellular nanovesicles

The MICROBE project aims to develop innovative BEV nanotherapeutics from gut bacteria to enhance immune checkpoint inhibitor responses in cancer treatment through mechanistic analysis and clinical application.

€ 2.000.000
ERC STG

Microbial Synthetic in vivo Cell Therapy Systems

The MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways.

€ 1.499.938
ERC ADG

Breaking resistance of pathogenic bacteria by chemical dysregulation

The project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy.

€ 2.499.785